BioNTech (BNTX) Q4 2025 earnings summary

Executive summary

• Achieved strong COVID-19 vaccine market leadership with over 50% share in key markets and launched a variant-adapted vaccine.

• Advanced late-stage oncology pipeline, with over 25 phase 2 & 3 trials, multiple phase III trials initiated, and key readouts expected in 2026.

• Announced creation of a new independent company for next-generation mRNA innovations, with founders transitioning by end of 2026.

• Ended 2025 with €17.2 billion in cash, cash equivalents, and securities, supporting a robust pipeline and future launches.

• CEO and CMO succession planning underway, with transitions expected by end of 2026.

Financial highlights

• FY 2025 revenues reached €2.87 billion, exceeding guidance (€2.6–2.8 billion), with Q4 2025 revenues at €907 million.

• FY 2025 IFRS net loss was €1.14 billion; adjusted net loss was €117 million.

• R&D expenses for 2025 were approximately €2.1 billion (adjusted: €2.02 billion); SG&A expenses: €624.4 million.

• Recognized €613 million in revenue from BMS collaboration upfront and anniversary payments.

• Cash and securities as of December 31, 2025, totaled €17.2 billion.

Outlook and guidance

• FY 2026 revenue guidance: €2.0–2.3 billion, reflecting lower COVID-19 vaccine sales in US and Europe.

• Adjusted R&D expenses for 2026 expected at €2.2–2.5 billion; adjusted SG&A at €700–800 million.

• Multiple late-stage clinical readouts and regulatory submissions anticipated in 2026.

• Revenue guidance reflects competitive U.S. market, contract transitions in Europe, and stable BMS collaboration revenues.